Antibody Information
General Information of This Antibody
| Antibody ID | ANI0LSSVU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | DI-B4-(LC)-GGGGGGG-CVIM |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | B-lymphocyte antigen CD19 (CD19) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-CD19(LC)-G7VIM-2i [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
110 ng/mL
|
Positive CD19 expression (CD19 +++/++) | ||
| Method Description |
Raji cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°C in 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Negative CD19 expression (CD19 -) | ||
| Method Description |
K562 cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°Cin 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
|
||||
| In Vitro Model | Chronic myeloid leukemia | K562 cells | CVCL_0004 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.